Abstract
The design and synthesis of a new potent and selective inhibitor of the respiratory syncytial virus are described. This compound, RFI-641, emerged from analysis of the structure-activity relationship in a series of biphenyl triazine anionic compounds possessing specific anti-RSV activity. The key synthetic step involves coupling of diaminobiphenyl 11 with two equivalents of chlorotriazine 10 under microwave conditions. RFI-641 inhibited RSV in vitro and in vivo models.
MeSH terms
-
Animals
-
Antiviral Agents / chemical synthesis
-
Antiviral Agents / pharmacology*
-
Cells, Cultured
-
Chlorocebus aethiops
-
Cytomegalovirus / drug effects*
-
Disease Models, Animal
-
Drug Design
-
Enzyme-Linked Immunosorbent Assay
-
Herpesvirus 1, Human / drug effects*
-
Humans
-
Inhibitory Concentration 50
-
Mice
-
Nose / virology
-
Rats
-
Respiratory Syncytial Virus Infections / drug therapy
-
Respiratory Syncytial Viruses / drug effects*
-
Sensitivity and Specificity
-
Structure-Activity Relationship
-
Sulfonamides / chemical synthesis
-
Sulfonamides / pharmacology*
-
Triazenes / chemical synthesis
-
Triazenes / pharmacology
-
Triazines / chemical synthesis
-
Triazines / pharmacology*
Substances
-
Antiviral Agents
-
RFI 641
-
Sulfonamides
-
Triazenes
-
Triazines